E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Myotonic disorders are divided into dystrophic myotonias (DM1 and DM2) and non-dystrophic myotonias (NDM). The dystrophic myotonias are associated with significant progressive muscular weakness and other systemic organ involvement. On the other hand, NDM usually presents with muscle stiffness as the primary symptom, and severe weakness is not considered a major feature, especially in myotonia congenita. |
Miotonie non distrofiche, cioe' le canalopatie scheletriche del cloro (es. miotonia congenita di Thomsen e di Becker) e del sodio (es. paralisi periodica ipercaliemica, paramiotonia congenita, miotonia aggravata dal potassio, acetazolamide-sensibile) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10032487 |
E.1.2 | Term | Other specific muscle disorders |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The specific aim of this proposal is to perform a randomized, double-blind, placebo-controlled crossover study to assess whether mexiletine improves both quantitative and qualitative measures of myotonia in patients with non-dystrophic myotonia. |
Lo scopo di questo studio randomizzato, in doppio cieco, cross-over, controllato verso placebo e' quello di determinare se la mexiletina e' un farmaco efficace nelle miotonie non distrofiche |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
At least 16 years of age 2. Clinical symptoms or signs suggestive of myotonic disorders 3. Presence of myotonic potentials on electromyography (EMG) 4. Participation in the Non-Dystrophic Myotonia Natural History study or a new patient with genetic confirmed NDM |
1. < 16 anni 2. sintomi o segni clinici evocativi di miotonia 3. riscontro di scariche miotoniche allo studio EMG 4. paziente con diagnosi genetica di miotonia non distrofica |
|
E.4 | Principal exclusion criteria |
Inability or unwillingness to provide informed consent. 2. Other neurological conditions that might affect the assessment of the study measurements. 3. Genetic confirmed DM1 (CTG > 50 repeats), or DM2. 4. Patients with existing cardiac conduction defects, evidenced on EKG including but not limited to the following conditions: malignant arrhythmia or cardiac conduction disturbances (such as second degree AV block, third degree AV block, or prolonged QT interval >500 ms or QRS duration > 150 msec). 5. Current use of the following antiarrhythmic medication for a cardiac disorder: flecainide acetate, encainide, disopyramide, procainamide, quinidine, propafenone or mexiletine. 6. Women who are pregnant or lactating. 7. Patients currently on medications for myotonia such as phenytoin and flecainide acetate within 5 days of enrollment, carbamazepine and mexiletine within 3 days of enrollment, or propafenone, procainamide, disopyramide, quinidine and encainide within 2 days of enrollment. 8. Patients with an existing permanent pacemaker. 9. Patients with renal or hepatic disease, heart failure, or seizure disorders. 10. Patients on medications that produce myotonia. This includes one or more of the following: a. fibrate acid derivatives, b. hydroxymethylglutaryl CoA reductase inhibitors c. chloroquine d. colchicines |
1.mancanza di consenso informato 2. altre condizioni neurologiche che potrebbero interferire con il completamento dello studio (es disordini cognitivi/comportamentali associati; deficit neuroperiferico che interferisca con l uso corretto delle mani; disordini motori associati che interferiscano con la possibilita' di recarsi alle visite di controllo, ecc.) 3. conferma genetica di distrofia miotonica di Steinert, di tipo 1 (CTG > 50) o di distrofia miotonica di tipo 2 (DM2) 4. pazienti con difetti di conduzione cardiaca sulla base del dato ECG che includano tra alti difetti: aritmie maggiori, disturbi di conduzione cardiaca (blocco AV di II grado o di III grado, intervallo QTc corretto allungato > 500msec o un allungamento della durata del QRS > 150 msec. 5. Utilizzo regolare di terapia antiaritmica per cause cardiologiche: flecainide acetato, encainide, disopiramide, procainamide, chinidina, propafenone, mexiletina. 6. Donne gravide o in allattamento 7. Pazienti che abbiano iniziato il trattamento antimiotonico con i seguenti farmaci: fenitoina e flecainide entro 5 giorni dall arruolamento; carbamazepina e mexiletina entro 3 giorni dall arruolamento; propafenone, procainamide, disopiramide, chinidina ed encainide entro 2 giorni dall arruolamento. 8. Pazienti portatori di pacemaker permanente 9. Pazienti con insufficienza epatica, cardiaca o epilettici 10. Pazienti in terapia con farmaci che possono indurre miotonia. Questi includono: - fibrati - inibitori della idrossimetilglutaril CoA reduttasi - clorochina - colchicina |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Participant-assessed stiffness as measured by IVR. Data from the NDM natural history study has shown that stiffness is the most common symptom NDM patients encountered; and there is minimal variation of the reported symptom frequency from week to week (Wang, 2007). Therefore, the primary outcome measure will be the mean daily IVR participantassessed severity of stiffness in weeks 2 & 3, and 7 & 8. |
La modifica della miotonia valutata dai pazienti utilizzando diari elettronici. L end-point primario sara' la media del punteggio relativo alla severita' della miotonia segnalata alla 2a e 3a settimana e la media del punteggio relativo segnalata alla 7a e 8a settimana. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Regole di conclusione anticipata (Early stopping rules), come indicate nel protocollo |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |